Becton, Dickinson and Company (BDX)
| Market Cap | 59.39B +7.8% |
| Revenue (ttm) | 19.46B -10.9% |
| Net Income | 1.15B -31.8% |
| EPS | 4.09 -29.7% |
| Shares Out | 272.39M |
| PE Ratio | 53.28 |
| Forward PE | 16.50 |
| Dividend | $4.24 (1.95%) |
| Ex-Dividend Date | Dec 10, 2026 |
| Volume | 1,879,895 |
| Open | 217.23 |
| Previous Close | 215.71 |
| Day's Range | 216.38 - 219.78 |
| 52-Week Range | 140.11 - 219.78 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 226.14 (+3.72%) |
| Earnings Date | Nov 5, 2026 |
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, va... [Read more]
Financial Performance
In fiscal year 2026, BDX's revenue was $19.46 billion, a decrease of -10.91% compared to the previous year's $21.84 billion. Earnings were $1.15 billion, a decrease of -31.76%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for BDX stock is "Buy." The 12-month stock price target is $226.14, which is an increase of 3.72% from the latest price.
News
BD to Host Investor Day on December 10, 2026
FRANKLIN LAKES, N.J., Nov. 10, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host an Investor Day for i...
Becton Dickinson price target raised to $195 from $165 at Barclays
Barclays analyst Christopher Pasquale raised the firm’s price target on Becton Dickinson (BDX) to $195 from $165 and keeps an Underweight rating on the shares. The firm views fiscal 2027…
Becton Dickinson price target raised to $225 from $200 at BofA
BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $225 from $200 and keeps a Neutral rating on the shares. The company’s fiscal 2027 outlook…
Becton Dickinson price target raised to $225 from $190 at RBC Capital
RBC Capital raised the firm’s price target on Becton Dickinson (BDX) to $225 from $190 and keeps a Sector Perform rating on the shares. The company delivered a solid Q4…
Becton Dickinson price target raised to $220 from $188 at JPMorgan
JPMorgan raised the firm’s price target on Becton Dickinson (BDX) to $220 from $188 and keeps a Neutral rating on the shares.
Becton Dickinson price target raised to $200 from $175 at Piper Sandler
Piper Sandler analyst Jason Bednar raised the firm’s price target on Becton Dickinson (BDX) to $200 from $175 and keeps a Neutral rating on the shares following quarterly results. Management…
Becton Dickinson price target raised to $241 from $208 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Becton Dickinson (BDX) to $241 from $208 and keeps a Buy rating on the shares.
Becton Dickinson upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded Becton Dickinson (BDX) to Overweight from Equal Weight with a price target of $242, up from $170. The firm is citing the company’s improved execution in the…
Becton Dickinson price target raised to $235 from $195 at Stifel
Stifel raised the firm’s price target on Becton Dickinson (BDX) to $235 from $195 and keeps a Buy rating on the shares after a better-than-expected fiscal Q4 report. While the…
Becton Dickinson price target raised to $242 from $210 at Jefferies
Jefferies raised the firm’s price target on Becton Dickinson (BDX) to $242 from $210 and keeps a Buy rating on the shares following Q4 results. Jefferies views FY27 guidance as…
Becton, Dickinson and Company Earnings Call Transcript: Q4 2026
Q4 and FY results showed broad growth, margin gains in Q4, and a sharp increase in free cash flow. FY 2027 guidance reflects Alaris and tariff headwinds, while excluding Alaris, revenue growth is expected at mid-single digits.
Becton, Dickinson and Company Slides: Q4 2026
Becton, Dickinson and Company has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on November 5, 2026.
Becton, Dickinson and Company Earnings release: Q4 2026
Becton, Dickinson and Company released its Q4 2026 earnings on November 5, 2026, summarizing the period's financial results.
Becton Dickinson increases quarterly dividend, share repurchase program
The board of directors of Becton Dickinson (BDX) has declared a quarterly dividend of $1.06 per common share, an increase of 1% from the previous quarter. The dividend will be…
BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
Q4 revenue of $5.3 billion increased 5.4% as reported, 5.6% FXN Q4 GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively FY26 revenue of $19.5 billion increased 4.9% as reported, 3.9% FXN FY2...
BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
FRANKLIN LAKES, N.J., Nov. 5, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has declared a quarterly divid...
BD Names Bridget Bagnato Worldwide President of Peripheral Intervention
FRANKLIN LAKES, N.J., Nov. 4, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Bridget Bagnato has been appointed ...
Becton Dickinson launches Liverty stent graft for portal hypertension in U.S.
Becton Dickinson (BDX) announced the U.S. commercial launch of the Liverty TIPS Stent Graft, advancing portal hypertension care by giving physicians greater flexibility to tailor treatment to each pat...
BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
The launch of the Liverty™ TIPS Stent Graft gives physicians flexibility to tailor treatment for patients. FRANKLIN LAKES, N.J.
BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
FRANKLIN LAKES, N.J., Oct. 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio we...
BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
Physicians, policymakers, and global health experts urge broader access to monitoring technologies that can help identify life-threatening complications earlier, helping more mothers survive childbirt...
Becton Dickinson initiated with an Underweight at Barclays (yesterday)
Barclays analyst Christopher Pasquale last night initiated coverage of Becton Dickinson (BDX) with an Underweight rating and $165 price target The firm rolled out coverage of the medical suppliers and...
BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence s...
BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
Generations of Connecticut employees have helped ensure the reliable supply of the BD® Syringe, an essential medical device clinicians rely on every day in patient care around the world CANAAN, Conn.,...
Becton Dickinson (BDX) Joins Trump Tariff Exemption Scramble with $19B Investment Plan
U.S. medical device company Becton Dickinson ($BDX) has agreed to invest $19 billion in the U.S. over several years, the company announced in a statement on Tuesday. In return, the…